Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ATAI Life Sciences NV ATAI

Healthcare Biotechnology
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B... see more

Recent & Breaking News (NDAQ:ATAI)

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire November 13, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GlobeNewswire November 11, 2024

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 15, 2024

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire August 13, 2024

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

GlobeNewswire August 13, 2024

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

GlobeNewswire August 7, 2024

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

GlobeNewswire June 26, 2024

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

GlobeNewswire June 20, 2024

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

GlobeNewswire May 31, 2024

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

GlobeNewswire May 23, 2024

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire May 15, 2024

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

GlobeNewswire April 24, 2024

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

GlobeNewswire April 17, 2024

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

GlobeNewswire March 28, 2024

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

GlobeNewswire March 27, 2024

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

GlobeNewswire March 4, 2024

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

GlobeNewswire February 6, 2024

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

GlobeNewswire January 4, 2024